JP2016535784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535784A5 JP2016535784A5 JP2016552453A JP2016552453A JP2016535784A5 JP 2016535784 A5 JP2016535784 A5 JP 2016535784A5 JP 2016552453 A JP2016552453 A JP 2016552453A JP 2016552453 A JP2016552453 A JP 2016552453A JP 2016535784 A5 JP2016535784 A5 JP 2016535784A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrazole
- dihydrochromeno
- carboxamido
- fluorobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 63
- 150000001875 compounds Chemical class 0.000 claims description 61
- 239000002253 acid Substances 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 239000005711 Benzoic acid Substances 0.000 claims description 31
- 235000010233 benzoic acid Nutrition 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 16
- 102100038495 Bile acid receptor Human genes 0.000 claims description 12
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 12
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 11
- 206010008635 Cholestasis Diseases 0.000 claims description 10
- -1 N- (2-fluorobenzyl) -1-methyl-1,4-dihydrochromeno [4,3-c] pyrazole-3-carboxamido Chemical group 0.000 claims description 10
- 230000007870 cholestasis Effects 0.000 claims description 10
- 231100000359 cholestasis Toxicity 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000006413 ring segment Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 7
- 208000019423 liver disease Diseases 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- FWXWRVYLLDLGNU-UHFFFAOYSA-N 8-fluoro-N-[(2-fluorophenyl)methyl]-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carboxamide Chemical compound FC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)NCC1=C(C=CC=C1)F)C FWXWRVYLLDLGNU-UHFFFAOYSA-N 0.000 claims description 5
- JYTIXGYXBIBOMN-UHFFFAOYSA-N nidufexor Chemical compound Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(O)=O)c2COc3ccc(Cl)cc3-c12 JYTIXGYXBIBOMN-UHFFFAOYSA-N 0.000 claims description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 239000003613 bile acid Substances 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 235000016236 parenteral nutrition Nutrition 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- FSJRFMYCVARFJU-UHFFFAOYSA-N 3-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethoxy]benzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2cccc(c2)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 FSJRFMYCVARFJU-UHFFFAOYSA-N 0.000 claims description 3
- LYVMCHZYDPLRTR-UHFFFAOYSA-N 3-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethylamino]benzoic acid Chemical compound Cn1nc(C(=O)N(CCNc2cccc(c2)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 LYVMCHZYDPLRTR-UHFFFAOYSA-N 0.000 claims description 3
- LRPVFIZBQAZGFZ-UHFFFAOYSA-N 3-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]ethylamino]-4-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCNc2cc(ccc2F)C(O)=O)Cc2cccc(F)c2)c2COc3ccc(Cl)cc3-c12 LRPVFIZBQAZGFZ-UHFFFAOYSA-N 0.000 claims description 3
- IQIHHXCDAAIRAM-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]methyl]benzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccc(cc2)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 IQIHHXCDAAIRAM-UHFFFAOYSA-N 0.000 claims description 3
- AUCJHDHYRSXPGJ-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]methyl]benzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccc(cc2)C(O)=O)Cc2cccc(F)c2)c2COc3ccc(Cl)cc3-c12 AUCJHDHYRSXPGJ-UHFFFAOYSA-N 0.000 claims description 3
- YMOMNUUERLHSSV-UHFFFAOYSA-N 4-fluoro-3-[2-[(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]ethylamino]benzoic acid Chemical compound Cn1nc(C(=O)N(CCNc2cc(ccc2F)C(O)=O)Cc2cccc(F)c2)c2COc3ccc(F)cc3-c12 YMOMNUUERLHSSV-UHFFFAOYSA-N 0.000 claims description 3
- WUTSLVYMBGNFGH-UHFFFAOYSA-N 8-fluoro-N-[(3-fluorophenyl)methyl]-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carboxamide Chemical compound FC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)NCC1=CC(=CC=C1)F)C WUTSLVYMBGNFGH-UHFFFAOYSA-N 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- IMDAWGZBLRKXIE-UHFFFAOYSA-N 1-[[[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]acetyl]amino]methyl]cyclopropane-1-carboxylic acid Chemical compound ClC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)N(CC1=C(C=CC=C1)F)CC(=O)NCC1(CC1)C(=O)O)C IMDAWGZBLRKXIE-UHFFFAOYSA-N 0.000 claims description 2
- AONSLHFVFSDBGZ-UHFFFAOYSA-N 3-[2-[(7,8-difluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]ethylamino]-4-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCNc2cc(ccc2F)C(O)=O)Cc2cccc(F)c2)c2COc3cc(F)c(F)cc3-c12 AONSLHFVFSDBGZ-UHFFFAOYSA-N 0.000 claims description 2
- OUAXPCFXYLDFRI-UHFFFAOYSA-N 3-[2-[(7,8-difluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-methylphenyl)methyl]amino]ethylamino]-4-fluorobenzoic acid Chemical compound Cc1cccc(CN(CCNc2cc(ccc2F)C(O)=O)C(=O)c2nn(C)c-3c2COc2cc(F)c(F)cc-32)c1 OUAXPCFXYLDFRI-UHFFFAOYSA-N 0.000 claims description 2
- PDRYWSXZQFRPQR-UHFFFAOYSA-N 3-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethoxy]-4-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2cc(ccc2F)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 PDRYWSXZQFRPQR-UHFFFAOYSA-N 0.000 claims description 2
- VKWOWOMXUPXAMP-UHFFFAOYSA-N 3-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-methylphenyl)methyl]amino]ethylamino]-4-fluorobenzoic acid Chemical compound Cc1cccc(CN(CCNc2cc(ccc2F)C(O)=O)C(=O)c2nn(C)c-3c2COc2ccc(Cl)cc-32)c1 VKWOWOMXUPXAMP-UHFFFAOYSA-N 0.000 claims description 2
- HIYVXBLCLCKENU-UHFFFAOYSA-N 3-[2-[benzyl-(7,8-difluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethylamino]-4-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCNc2cc(ccc2F)C(O)=O)Cc2ccccc2)c2COc3cc(F)c(F)cc3-c12 HIYVXBLCLCKENU-UHFFFAOYSA-N 0.000 claims description 2
- NYZPDZBXJAVCNO-UHFFFAOYSA-N 3-[2-[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethylamino]-4-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCNc2cc(ccc2F)C(O)=O)Cc2ccccc2)c2COc3ccc(Cl)cc3-c12 NYZPDZBXJAVCNO-UHFFFAOYSA-N 0.000 claims description 2
- FFTIMDOOUCFJRA-UHFFFAOYSA-N 3-[2-[benzyl-(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethylamino]-4-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCNc2cc(ccc2F)C(O)=O)Cc2ccccc2)c2COc3ccc(F)cc3-c12 FFTIMDOOUCFJRA-UHFFFAOYSA-N 0.000 claims description 2
- DKTKXEQFYHWHHL-UHFFFAOYSA-N 3-[[2-[(1,8-dimethyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]acetyl]amino]benzoic acid Chemical compound Cc1ccc2OCc3c(nn(C)c3-c2c1)C(=O)N(CC(=O)Nc1cccc(c1)C(O)=O)Cc1ccccc1F DKTKXEQFYHWHHL-UHFFFAOYSA-N 0.000 claims description 2
- BNDBVALGKOEGJJ-UHFFFAOYSA-N 3-fluoro-4-[[(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]methyl]benzoic acid Chemical compound FC=1C=C(C(=O)O)C=CC1CN(C(=O)C=1C2=C(N(N1)C)C=1C=C(C=CC1OC2)F)CC2=C(C=CC=C2)F BNDBVALGKOEGJJ-UHFFFAOYSA-N 0.000 claims description 2
- JPDGNBLMRHRLTN-UHFFFAOYSA-N 3-fluoro-4-[[(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-methylphenyl)methyl]amino]methyl]benzoic acid Chemical compound Cc1cccc(CN(Cc2ccc(cc2F)C(O)=O)C(=O)c2nn(C)c-3c2COc2ccc(F)cc-32)c1 JPDGNBLMRHRLTN-UHFFFAOYSA-N 0.000 claims description 2
- AZQSCICKUHOZOX-UHFFFAOYSA-N 4-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-(cyclopentylmethyl)amino]ethoxy]-3,5-dimethylbenzoic acid Chemical compound Cc1cc(cc(C)c1OCCN(CC1CCCC1)C(=O)c1nn(C)c-2c1COc1ccc(Cl)cc-21)C(O)=O AZQSCICKUHOZOX-UHFFFAOYSA-N 0.000 claims description 2
- XIDJZZCPABSJCW-UHFFFAOYSA-N 4-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethoxy]-3,5-difluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2c(F)cc(cc2F)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 XIDJZZCPABSJCW-UHFFFAOYSA-N 0.000 claims description 2
- BYGKMYHAYBMJMM-UHFFFAOYSA-N 4-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethoxy]-3,5-dimethylbenzoic acid Chemical compound Cc1cc(cc(C)c1OCCN(Cc1ccccc1F)C(=O)c1nn(C)c-2c1COc1ccc(Cl)cc-21)C(O)=O BYGKMYHAYBMJMM-UHFFFAOYSA-N 0.000 claims description 2
- XFQFNZQSKREHRE-UHFFFAOYSA-N 4-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethoxy]-3-(trifluoromethyl)benzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2ccc(cc2C(F)(F)F)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 XFQFNZQSKREHRE-UHFFFAOYSA-N 0.000 claims description 2
- YPNFQWNWBXQXPH-UHFFFAOYSA-N 4-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethoxy]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2ccc(cc2F)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 YPNFQWNWBXQXPH-UHFFFAOYSA-N 0.000 claims description 2
- BOOUDOVTRORLGS-UHFFFAOYSA-N 4-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethoxy]benzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2ccc(cc2)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 BOOUDOVTRORLGS-UHFFFAOYSA-N 0.000 claims description 2
- SMJHCJJTEVTFLW-UHFFFAOYSA-N 4-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]ethoxy]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2ccc(cc2F)C(O)=O)Cc2cccc(F)c2)c2COc3ccc(Cl)cc3-c12 SMJHCJJTEVTFLW-UHFFFAOYSA-N 0.000 claims description 2
- ZVYKQLMAEOESRQ-UHFFFAOYSA-N 4-[2-[benzyl-(7,8-difluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethoxy]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2ccc(cc2F)C(O)=O)Cc2ccccc2)c2COc3cc(F)c(F)cc3-c12 ZVYKQLMAEOESRQ-UHFFFAOYSA-N 0.000 claims description 2
- OQNSPIUYFRIRCH-UHFFFAOYSA-N 4-[2-[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethoxy]-3,5-difluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2c(F)cc(cc2F)C(O)=O)Cc2ccccc2)c2COc3ccc(Cl)cc3-c12 OQNSPIUYFRIRCH-UHFFFAOYSA-N 0.000 claims description 2
- JZCFSXBSTOWTKD-UHFFFAOYSA-N 4-[2-[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethoxy]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2ccc(cc2F)C(O)=O)Cc2ccccc2)c2COc3ccc(Cl)cc3-c12 JZCFSXBSTOWTKD-UHFFFAOYSA-N 0.000 claims description 2
- ULAMPKYWOCISHL-UHFFFAOYSA-N 4-[2-[benzyl-(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethoxy]-3,5-difluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2c(F)cc(cc2F)C(O)=O)Cc2ccccc2)c2COc3ccc(F)cc3-c12 ULAMPKYWOCISHL-UHFFFAOYSA-N 0.000 claims description 2
- RQLKTWUCUCJISI-UHFFFAOYSA-N 4-[2-[benzyl-(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethoxy]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCOc2ccc(cc2F)C(O)=O)Cc2ccccc2)c2COc3ccc(F)cc3-c12 RQLKTWUCUCJISI-UHFFFAOYSA-N 0.000 claims description 2
- QNHJQIUNQURVID-UHFFFAOYSA-N 4-[[(3,5-difluorophenyl)methyl-(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccc(cc2)C(O)=O)Cc2cc(F)cc(F)c2)c2COc3ccc(F)cc3-c12 QNHJQIUNQURVID-UHFFFAOYSA-N 0.000 claims description 2
- PWAIFGUTQDTORG-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-(1H-indol-5-ylmethyl)amino]methyl]benzoic acid Chemical compound N1C=CC2=CC(=CC=C12)CN(C(=O)C=1C2=C(N(N1)C)C=1C=C(C=CC1OC2)Cl)CC2=CC=C(C(=O)O)C=C2 PWAIFGUTQDTORG-UHFFFAOYSA-N 0.000 claims description 2
- ASAGXPHLRIABEH-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2,3-difluorophenyl)methyl]amino]methyl]benzoic acid Chemical compound ClC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)N(CC1=C(C(=CC=C1)F)F)CC1=CC=C(C(=O)O)C=C1)C ASAGXPHLRIABEH-UHFFFAOYSA-N 0.000 claims description 2
- AIKMRRXUJZVITP-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]methyl]-2-fluorobenzoic acid Chemical compound ClC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)N(CC1=C(C=CC=C1)F)CC1=CC(=C(C(=O)O)C=C1)F)C AIKMRRXUJZVITP-UHFFFAOYSA-N 0.000 claims description 2
- LIBJDTRMQPEPNY-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]methyl]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccccc2F)Cc2ccc(cc2F)C(O)=O)c2COc3ccc(Cl)cc3-c12 LIBJDTRMQPEPNY-UHFFFAOYSA-N 0.000 claims description 2
- UQQMPQAPKULNGX-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3,5-difluorophenyl)methyl]amino]methyl]benzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccc(cc2)C(O)=O)Cc2cc(F)cc(F)c2)c2COc3ccc(Cl)cc3-c12 UQQMPQAPKULNGX-UHFFFAOYSA-N 0.000 claims description 2
- RXVZGZPKRSNTGR-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluoro-5-methylphenyl)methyl]amino]methyl]benzoic acid Chemical compound Cc1cc(F)cc(CN(Cc2ccc(cc2)C(O)=O)C(=O)c2nn(C)c-3c2COc2ccc(Cl)cc-32)c1 RXVZGZPKRSNTGR-UHFFFAOYSA-N 0.000 claims description 2
- KRWBWJRLLXSGJQ-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]methyl]-2-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(Cc2cccc(F)c2)Cc2ccc(C(O)=O)c(F)c2)c2COc3ccc(Cl)cc3-c12 KRWBWJRLLXSGJQ-UHFFFAOYSA-N 0.000 claims description 2
- WGTXKQXGMOALMS-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]methyl]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(Cc2cccc(F)c2)Cc2ccc(cc2F)C(O)=O)c2COc3ccc(Cl)cc3-c12 WGTXKQXGMOALMS-UHFFFAOYSA-N 0.000 claims description 2
- OISCITBTBYYNPZ-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-methylphenyl)methyl]amino]methyl]-3-fluorobenzoic acid Chemical compound Cc1cccc(CN(Cc2ccc(cc2F)C(O)=O)C(=O)c2nn(C)c-3c2COc2ccc(Cl)cc-32)c1 OISCITBTBYYNPZ-UHFFFAOYSA-N 0.000 claims description 2
- WKWJLMDNSULFGY-UHFFFAOYSA-N 4-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-methylphenyl)methyl]amino]methyl]benzoic acid Chemical compound Cc1cccc(CN(Cc2ccc(cc2)C(O)=O)C(=O)c2nn(C)c-3c2COc2ccc(Cl)cc-32)c1 WKWJLMDNSULFGY-UHFFFAOYSA-N 0.000 claims description 2
- CIRYTQMPVZUZPH-UHFFFAOYSA-N 4-[[(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]methyl]benzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccc(cc2)C(O)=O)Cc2cccc(F)c2)c2COc3ccc(F)cc3-c12 CIRYTQMPVZUZPH-UHFFFAOYSA-N 0.000 claims description 2
- GJNULYRFVCWOQT-UHFFFAOYSA-N 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]-2-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(C(O)=O)c(F)c2)c2COc3ccc(Cl)cc3-c12 GJNULYRFVCWOQT-UHFFFAOYSA-N 0.000 claims description 2
- HJBFMXAWFGCWBE-UHFFFAOYSA-N 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2F)C(O)=O)c2COc3ccc(Cl)cc3-c12 HJBFMXAWFGCWBE-UHFFFAOYSA-N 0.000 claims description 2
- BMUMHLCCNNCEMA-UHFFFAOYSA-N 4-[[benzyl-(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]-3-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2F)C(O)=O)c2COc3ccc(F)cc3-c12 BMUMHLCCNNCEMA-UHFFFAOYSA-N 0.000 claims description 2
- YCUGJRWGKWZVKB-UHFFFAOYSA-N 4-fluoro-3-[2-[(2-fluorophenyl)methyl-(1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]ethylamino]benzoic acid Chemical compound FC1=C(C=C(C(=O)O)C=C1)NCCN(C(=O)C=1C2=C(N(N1)C)C=1C=CC=CC1OC2)CC2=C(C=CC=C2)F YCUGJRWGKWZVKB-UHFFFAOYSA-N 0.000 claims description 2
- NOKLTKFAVVUZDY-UHFFFAOYSA-N 4-fluoro-3-[2-[(8-fluoro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethylamino]benzoic acid Chemical compound FC1=C(C=C(C(=O)O)C=C1)NCCN(C(=O)C=1C2=C(N(N1)C)C=1C=C(C=CC1OC2)F)CC2=C(C=CC=C2)F NOKLTKFAVVUZDY-UHFFFAOYSA-N 0.000 claims description 2
- OIPRUMTZVHIJMF-UHFFFAOYSA-N 5-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]methyl]-6-methylpyridine-2-carboxylic acid Chemical compound Cc1nc(ccc1CN(Cc1cccc(F)c1)C(=O)c1nn(C)c-2c1COc1ccc(Cl)cc-21)C(O)=O OIPRUMTZVHIJMF-UHFFFAOYSA-N 0.000 claims description 2
- PMLAYJDPZOLTFC-UHFFFAOYSA-N 5-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]methyl]pyridine-2-carboxylic acid Chemical compound Cn1nc(C(=O)N(Cc2ccc(nc2)C(O)=O)Cc2cccc(F)c2)c2COc3ccc(Cl)cc3-c12 PMLAYJDPZOLTFC-UHFFFAOYSA-N 0.000 claims description 2
- SFVZYOUTCCTGBV-UHFFFAOYSA-N 6-[[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]methyl]pyridine-3-carboxylic acid Chemical compound Cn1nc(C(=O)N(Cc2cccc(F)c2)Cc2ccc(cn2)C(O)=O)c2COc3ccc(Cl)cc3-c12 SFVZYOUTCCTGBV-UHFFFAOYSA-N 0.000 claims description 2
- VUWAWERWYDPEGE-UHFFFAOYSA-N 7,8-difluoro-N-[(2-fluorophenyl)methyl]-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carboxamide Chemical compound FC=1C(=CC2=C(C1)OCC1=C2N(N=C1C(=O)NCC1=C(C=CC=C1)F)C)F VUWAWERWYDPEGE-UHFFFAOYSA-N 0.000 claims description 2
- QVAVUSJZRGGGPN-UHFFFAOYSA-N 7,8-difluoro-N-[(3-fluorophenyl)methyl]-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carboxamide Chemical compound FC=1C(=CC2=C(C=1)OCC1=C2N(N=C1C(=O)NCC1=CC(=CC=C1)F)C)F QVAVUSJZRGGGPN-UHFFFAOYSA-N 0.000 claims description 2
- MMFSVGMDEQSRJF-UHFFFAOYSA-N 8-fluoro-1-methyl-N-[(3-methylphenyl)methyl]-4H-chromeno[4,3-c]pyrazole-3-carboxamide Chemical compound FC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)NCC1=CC(=CC=C1)C)C MMFSVGMDEQSRJF-UHFFFAOYSA-N 0.000 claims description 2
- 201000011374 Alagille syndrome Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- YIYWROIVNHFJQI-UHFFFAOYSA-N C(C)(=O)N.ClC1=CC2=C(OCCC3=C2N(N=C3C(=O)NCC3=C(C=CC=C3)F)C)C=C1 Chemical compound C(C)(=O)N.ClC1=CC2=C(OCCC3=C2N(N=C3C(=O)NCC3=C(C=CC=C3)F)C)C=C1 YIYWROIVNHFJQI-UHFFFAOYSA-N 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- SIURHGWBBDXCFH-UHFFFAOYSA-N ClC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)NCC=1C=NC=C(C=1)Cl)C Chemical compound ClC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)NCC=1C=NC=C(C=1)Cl)C SIURHGWBBDXCFH-UHFFFAOYSA-N 0.000 claims description 2
- QJMDAHZWFABRLA-UHFFFAOYSA-N ClC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)NCC=1C=NC=C(C=1)F)C Chemical compound ClC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)NCC=1C=NC=C(C=1)F)C QJMDAHZWFABRLA-UHFFFAOYSA-N 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010024715 Liver transplant rejection Diseases 0.000 claims description 2
- NAHCXGDLFTYZHZ-UHFFFAOYSA-N N-benzyl-N-[(4-carbamoylphenyl)methyl]-8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carboxamide Chemical compound Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(N)=O)c2COc3ccc(Cl)cc3-c12 NAHCXGDLFTYZHZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010057969 Reflux gastritis Diseases 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims description 2
- 230000007872 intrahepatic cholestasis Effects 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000035935 pregnancy Effects 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- ZVJWFAOFNQANPG-UHFFFAOYSA-N 8-chloro-N-[(2-fluorophenyl)methyl]-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carboxamide Chemical compound ClC1=CC2=C(C=C1)OCC1=C2N(N=C1C(=O)NCC1=C(C=CC=C1)F)C ZVJWFAOFNQANPG-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- UWIJYNIGCQPNBL-LJTMIZJLSA-N benzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound OC(=O)C1=CC=CC=C1.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO UWIJYNIGCQPNBL-LJTMIZJLSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940062165 meglumine benzoate Drugs 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- QMOGQRJWRSKJEO-UHFFFAOYSA-N ClC1=CC2=C(OCCC3=C2N(N=C3C(=O)NCC3=C(C=CC=C3)F)C)C=C1 Chemical compound ClC1=CC2=C(OCCC3=C2N(N=C3C(=O)NCC3=C(C=CC=C3)F)C)C=C1 QMOGQRJWRSKJEO-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- DTQKJSVGRYVELH-UHFFFAOYSA-N 3-[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]ethylamino]-4-fluorobenzoic acid Chemical compound Cn1nc(C(=O)N(CCNc2cc(ccc2F)C(O)=O)Cc2ccccc2F)c2COc3ccc(Cl)cc3-c12 DTQKJSVGRYVELH-UHFFFAOYSA-N 0.000 description 1
- VIRFTMXOCIDOFG-UHFFFAOYSA-N 3-[[2-[(9-chloro-1-methyl-4,5-dihydro-[1]benzoxepino[5,4-c]pyrazole-3-carbonyl)-[(2-fluorophenyl)methyl]amino]acetyl]amino]-4-fluoro-2-methylbenzoic acid Chemical compound CC1=C(C(=O)O)C=CC(=C1NC(CN(C(=O)C=1C2=C(N(N1)C)C1=C(OCC2)C=CC(=C1)Cl)CC1=C(C=CC=C1)F)=O)F VIRFTMXOCIDOFG-UHFFFAOYSA-N 0.000 description 1
- ZGGDSQVDUVGQMZ-UHFFFAOYSA-N 9-chloro-1-methyl-4,5-dihydro-[1]benzoxepino[5,4-c]pyrazole-3-carboxylic acid Chemical compound C1COC2=CC=C(Cl)C=C2C2=C1C(C(O)=O)=NN2C ZGGDSQVDUVGQMZ-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900013P | 2013-11-05 | 2013-11-05 | |
| US61/900,013 | 2013-11-05 | ||
| PCT/US2014/063948 WO2015069666A1 (en) | 2013-11-05 | 2014-11-04 | Compositions and methods for modulating farnesoid x receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535784A JP2016535784A (ja) | 2016-11-17 |
| JP2016535784A5 true JP2016535784A5 (cg-RX-API-DMAC7.html) | 2017-10-26 |
| JP6424231B2 JP6424231B2 (ja) | 2018-11-14 |
Family
ID=51982773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552453A Expired - Fee Related JP6424231B2 (ja) | 2013-11-05 | 2014-11-04 | ファルネソイドｘ受容体をモジュレートするための組成物および方法 |
Country Status (42)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| DK3065738T3 (en) | 2013-11-05 | 2018-06-06 | Novartis Ag | Compositions and Methods for Modulating Farnesoid X Receptors |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| US10351576B2 (en) * | 2015-04-30 | 2019-07-16 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors |
| KR20180115270A (ko) | 2016-02-22 | 2018-10-22 | 노파르티스 아게 | Fxr 효능제를 사용하는 방법 |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| KR102269305B1 (ko) | 2016-06-13 | 2021-06-25 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| RU2019110779A (ru) * | 2016-09-14 | 2020-10-15 | Новартис Аг | Новые схемы введения агонистов fxr |
| JP2019530696A (ja) * | 2016-10-05 | 2019-10-24 | ノバルティス アーゲー | 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物 |
| CN107973790A (zh) * | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| KR102643558B1 (ko) * | 2017-06-05 | 2024-03-06 | 내셔널 유니버시티 오브 싱가포르 | 인간 트레포일 인자 3을 억제하는데 유용한 화합물 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| CN111093773A (zh) | 2017-08-15 | 2020-05-01 | 英夫拉索姆有限公司 | 作为nlrp3抑制剂的磺酰脲和磺酰硫脲 |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| EP3681537A1 (en) * | 2017-09-13 | 2020-07-22 | Novartis AG | Combinations comprising fxr agonists |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| CN110128432B (zh) * | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| BR112021000964A2 (pt) | 2018-07-25 | 2021-04-20 | Novartis Ag | inibidores do inflamassoma de nlrp3 |
| DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
| US10610280B1 (en) | 2019-02-02 | 2020-04-07 | Ayad K. M. Agha | Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat |
| CN118388474A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2021044351A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
| CA3159163A1 (en) | 2020-01-15 | 2021-07-22 | Raphael Darteil | Use of fxr agonists for treating an infection by hepatitis d virus |
| CN113387828A (zh) * | 2020-03-14 | 2021-09-14 | 江巨东 | 一种阿利克仑中间体的制备方法 |
| WO2022037663A1 (zh) * | 2020-08-21 | 2022-02-24 | 苏州晶云药物科技股份有限公司 | 苯甲酸衍生物的新晶型及其制备方法 |
| US20240100125A1 (en) | 2021-01-14 | 2024-03-28 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| WO2024044778A2 (en) * | 2022-08-26 | 2024-02-29 | Celmatix Inc. | Novel modulators of fshr and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143449A1 (en) * | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| CA2651378C (en) * | 2006-05-24 | 2012-08-28 | Eli Lilly And Company | Fxr agonists |
| WO2008033534A2 (en) * | 2006-09-15 | 2008-03-20 | Thales Avionics, Inc. | System and method for wirelessly transferring content to and from an aircraft |
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| DK3065738T3 (en) | 2013-11-05 | 2018-06-06 | Novartis Ag | Compositions and Methods for Modulating Farnesoid X Receptors |
| US10351576B2 (en) | 2015-04-30 | 2019-07-16 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors |
-
2014
- 2014-11-04 DK DK14803001.8T patent/DK3065738T3/en active
- 2014-11-04 TR TR2018/07321T patent/TR201807321T4/tr unknown
- 2014-11-04 WO PCT/US2014/063948 patent/WO2015069666A1/en not_active Ceased
- 2014-11-04 CN CN201480058975.8A patent/CN105682656B/zh not_active Expired - Fee Related
- 2014-11-04 SI SI201430692T patent/SI3065738T1/en unknown
- 2014-11-04 SG SG11201603026PA patent/SG11201603026PA/en unknown
- 2014-11-04 NZ NZ719078A patent/NZ719078A/en not_active IP Right Cessation
- 2014-11-04 BR BR112016009630-4A patent/BR112016009630B1/pt not_active IP Right Cessation
- 2014-11-04 KR KR1020167014613A patent/KR102350357B1/ko not_active Expired - Fee Related
- 2014-11-04 PT PT148030018T patent/PT3065738T/pt unknown
- 2014-11-04 PL PL14803001T patent/PL3065738T3/pl unknown
- 2014-11-04 LT LTEP14803001.8T patent/LT3065738T/lt unknown
- 2014-11-04 PE PE2016000596A patent/PE20160682A1/es unknown
- 2014-11-04 ES ES14803001.8T patent/ES2670984T3/es active Active
- 2014-11-04 AU AU2014346919A patent/AU2014346919B2/en not_active Ceased
- 2014-11-04 CA CA2927705A patent/CA2927705C/en not_active Expired - Fee Related
- 2014-11-04 EA EA201690930A patent/EA030430B1/ru not_active IP Right Cessation
- 2014-11-04 EP EP14803001.8A patent/EP3065738B1/en active Active
- 2014-11-04 HR HRP20180817TT patent/HRP20180817T1/hr unknown
- 2014-11-04 MA MA39088A patent/MA39088B1/fr unknown
- 2014-11-04 TW TW103138253A patent/TWI662027B/zh not_active IP Right Cessation
- 2014-11-04 AP AP2016009165A patent/AP2016009165A0/en unknown
- 2014-11-04 US US15/034,280 patent/US9682939B2/en active Active
- 2014-11-04 CU CU2016000063A patent/CU24375B1/es unknown
- 2014-11-04 HU HUE14803001A patent/HUE039155T2/hu unknown
- 2014-11-04 UY UY0001035818A patent/UY35818A/es not_active Application Discontinuation
- 2014-11-04 TN TN2016000143A patent/TN2016000143A1/en unknown
- 2014-11-04 MX MX2016005865A patent/MX364834B/es active IP Right Grant
- 2014-11-04 JP JP2016552453A patent/JP6424231B2/ja not_active Expired - Fee Related
- 2014-11-04 RS RS20180524A patent/RS57179B1/sr unknown
- 2014-11-04 MY MYPI2016701351A patent/MY175903A/en unknown
- 2014-11-05 JO JOP/2014/0318A patent/JO3454B1/ar active
- 2014-11-05 AR ARP140104163A patent/AR098316A1/es unknown
-
2015
- 2015-03-17 NO NO15712554A patent/NO3105103T3/no unknown
-
2016
- 2016-04-14 ZA ZA2016/02555A patent/ZA201602555B/en unknown
- 2016-04-20 IL IL245242A patent/IL245242B/en active IP Right Grant
- 2016-04-25 CL CL2016000982A patent/CL2016000982A1/es unknown
- 2016-04-26 PH PH12016500777A patent/PH12016500777B1/en unknown
- 2016-05-05 SV SV2016005192A patent/SV2016005192A/es unknown
- 2016-05-05 CR CR20160212A patent/CR20160212A/es unknown
- 2016-05-05 GT GT201600085A patent/GT201600085A/es unknown
-
2017
- 2017-05-18 US US15/598,734 patent/US10077240B2/en active Active
-
2018
- 2018-05-24 CY CY20181100557T patent/CY1120273T1/el unknown
- 2018-08-07 US US16/056,881 patent/US10683271B2/en active Active
-
2020
- 2020-04-21 US US16/854,762 patent/US11021446B2/en not_active Expired - Fee Related
-
2021
- 2021-04-21 US US17/236,596 patent/US20210253534A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535784A5 (cg-RX-API-DMAC7.html) | ||
| TWI838626B (zh) | Lpa受體拮抗劑及其用途 | |
| CN105682656B (zh) | 调节法尼醇x受体的组合物和方法 | |
| JP2007500719A5 (cg-RX-API-DMAC7.html) | ||
| JP2013545718A5 (cg-RX-API-DMAC7.html) | ||
| TWI838747B (zh) | Ｌｐａ受體拮抗劑及其用途 | |
| JP2008519035A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512823A5 (cg-RX-API-DMAC7.html) | ||
| WO2007049532A1 (ja) | アミノジヒドロチアジン誘導体 | |
| JP2009527501A5 (cg-RX-API-DMAC7.html) | ||
| JP2007500716A5 (cg-RX-API-DMAC7.html) | ||
| JP2010501587A (ja) | ４−置換フェノキシフェニル酢酸誘導体 | |
| BRPI0713590A2 (pt) | derivados de pirrol com atividade de modulador de receptor de crth2 | |
| JP2013526494A5 (cg-RX-API-DMAC7.html) | ||
| AU2021282986A1 (en) | LPA receptor antagonists and uses thereof | |
| AU2019319745B2 (en) | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | |
| WO2007063925A1 (ja) | ２－アミノベンズアミド誘導体 | |
| JPH08506354A (ja) | ５−［２−（４−（ベンゾイソチアゾール−３−イル）−ピペラジン−１−イル）エチル−６−クロロ−１，３−ジヒドロ−インドール−２−オンの製造方法及び製造用中間体 | |
| NZ580381A (en) | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals | |
| CN101679370A (zh) | 香草素受体配体及其在制备药物中的用途 | |
| CN105884767A (zh) | 9-位取代的吡啶并[3,4-b]吲哚衍生物及其制备方法和作为SIRT蛋白抑制剂的用途 | |
| JPH06321879A (ja) | 治療用化合物 | |
| US20230045450A1 (en) | Process for preparing aficamten | |
| JP2020509005A (ja) | Ｎ−置換イミダゾールカルボン酸エステル系化合物とその調製方法及び用途 | |
| JP2017502999A (ja) | Ｒｘｒアゴニストとしての置換二環式ヘテロアリール化合物 |